vs
Beam Therapeutics Inc.（BEAM）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Resolute Holdings Management, Inc.的季度营收约是Beam Therapeutics Inc.的1.0倍（$117.7M vs $114.1M），Beam Therapeutics Inc.净利率更高（214.1% vs -1.5%，领先215.5%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
BEAM vs RHLD — 直观对比
营收规模更大
RHLD
是对方的1.0倍
$114.1M
净利率更高
BEAM
高出215.5%
-1.5%
自由现金流更多
RHLD
多$276.3M
$-87.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $117.7M |
| 净利润 | $244.3M | $-1.7M |
| 毛利率 | — | 55.7% |
| 营业利润率 | -15.3% | 30.2% |
| 净利率 | 214.1% | -1.5% |
| 营收同比 | 279.5% | — |
| 净利润同比 | 370.4% | — |
| 每股收益（稀释后） | $2.53 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMRHLD
| Q4 25 | $114.1M | $117.7M | ||
| Q3 25 | — | $120.9M | ||
| Q2 25 | — | $119.6M | ||
| Q1 25 | — | $103.9M | ||
| Q4 23 | $316.2M | — |
净利润BEAMRHLD
| Q4 25 | $244.3M | $-1.7M | ||
| Q3 25 | — | $-231.0K | ||
| Q2 25 | — | $-611.0K | ||
| Q1 25 | — | $-3.4M | ||
| Q4 23 | $142.8M | — |
毛利率BEAMRHLD
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 59.0% | ||
| Q2 25 | — | 57.5% | ||
| Q1 25 | — | 52.5% | ||
| Q4 23 | — | — |
营业利润率BEAMRHLD
| Q4 25 | -15.3% | 30.2% | ||
| Q3 25 | — | 34.3% | ||
| Q2 25 | — | 34.0% | ||
| Q1 25 | — | 24.7% | ||
| Q4 23 | 42.0% | — |
净利率BEAMRHLD
| Q4 25 | 214.1% | -1.5% | ||
| Q3 25 | — | -0.2% | ||
| Q2 25 | — | -0.5% | ||
| Q1 25 | — | -3.2% | ||
| Q4 23 | 45.2% | — |
每股收益（稀释后）BEAMRHLD
| Q4 25 | $2.53 | $-0.20 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.07 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 23 | $1.91 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | $1.2B | $6.5M |
| 总资产 | $1.5B | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资BEAMRHLD
| Q4 25 | $1.2B | $205.5M | ||
| Q3 25 | — | $148.0M | ||
| Q2 25 | — | $99.9M | ||
| Q1 25 | — | $71.0M | ||
| Q4 23 | $1.2B | — |
总债务BEAMRHLD
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 23 | — | — |
股东权益BEAMRHLD
| Q4 25 | $1.2B | $6.5M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | — | $9.6M | ||
| Q1 25 | — | $8.9M | ||
| Q4 23 | $981.3M | — |
总资产BEAMRHLD
| Q4 25 | $1.5B | $333.4M | ||
| Q3 25 | — | $293.2M | ||
| Q2 25 | — | $253.3M | ||
| Q1 25 | — | $214.3M | ||
| Q4 23 | $1.5B | — |
负债/权益比BEAMRHLD
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $189.2M |
| 自由现金流率自由现金流/营收 | -76.3% | 160.8% |
| 资本支出强度资本支出/营收 | 3.3% | 5.8% |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | $313.2M |
8季度趋势，按日历期对齐
经营现金流BEAMRHLD
| Q4 25 | $-83.3M | $196.1M | ||
| Q3 25 | — | $59.6M | ||
| Q2 25 | — | $48.9M | ||
| Q1 25 | — | $18.4M | ||
| Q4 23 | $135.1M | — |
自由现金流BEAMRHLD
| Q4 25 | $-87.0M | $189.2M | ||
| Q3 25 | — | $58.6M | ||
| Q2 25 | — | $47.5M | ||
| Q1 25 | — | $17.8M | ||
| Q4 23 | $131.5M | — |
自由现金流率BEAMRHLD
| Q4 25 | -76.3% | 160.8% | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 39.7% | ||
| Q1 25 | — | 17.1% | ||
| Q4 23 | 41.6% | — |
资本支出强度BEAMRHLD
| Q4 25 | 3.3% | 5.8% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 0.6% | ||
| Q4 23 | 1.1% | — |
现金转化率BEAMRHLD
| Q4 25 | -0.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 23 | 0.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
RHLD
暂无分部数据
